Ataxia Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1067428
  • December 2021
  • Healthcare
  • 125 Pages
Report Description

This report is a comprehensive study that examines the Ataxia industry in depth. With reference to key regions and major nations, the study specifies the product type of Ataxia as well as its use in various industrial verticals. Furthermore, the report identified and analysed all of the top companies functioning in the global Ataxia market arena, comparing and contrasting them based on market revenue, yearly sales volume, historical growth rate, and company strategies. The worldwide Ataxia market research offers a business strategy for current market participants to strengthen their market positions based on all of these findings. Furthermore, the paper recommends a market entry strategy for newcomers to the sector.

The top vendors and distributors operating in all of the major regions have also been highlighted in the Ataxia market report. This data and research should aid market players in strengthening their market distribution networks and expanding their geographic reach.
 
Ataxia Market Strategic Analysis 

The market was studied using several marketing methodologies such as Porter's Five Forces Analysis, player positioning analysis, SWOT analysis, market share analysis, and value chain analysis in the Ataxia market study. The market dynamics and factors such as the threat of a Ataxia substitute, the threat of new entrants into the Ataxia market, buyer bargaining power, supplier bargaining power to Ataxia providing companies, and internal rivalry among Ataxia providers are analysed in Porter's Five Forces analysis to provide the report's readers with a detailed view of the current market dynamics.

This analysis assists report users in evaluating the Ataxia market based on various parameters such as economies of scale, switching costs, brand loyalty, existing distribution channels, capital investments, manufacturing rights & patents, government regulations, advertising impact, and consumer preference impact. This simplified data is expected to aid the industry's key decision-makers in their decision-making process. Furthermore, this study answers the crucial question of whether or not new entrants should enter the Ataxia industry.
 
Ataxia Market Key Trends Analysis

The important factors influencing the growth of the Ataxia market have been examined in this report. The driving factors that are boosting demand for Ataxias and the restraining factors that are slowing growth of the Ataxia industry are addressed in depth, as well as their implications for the worldwide Ataxia market. In addition, the published analysis identifies and discusses in detail the trends that are driving the market and impacting its growth. In addition, other qualitative variables such as risks connected with operations and key problems faced by market players are covered in the report.

Ataxia Market Key Segment Analysis

By segmenting the market by product type, application, and geography, the study provides a clear picture of the Ataxia industry. On the basis of current and future trends, all segments of the Ataxia industry have been examined. The market and its divisions are forecasted for the years 2021 through 2028. The study identifies the categories that are contributing the most to total market revenue growth, as well as the factors that are supporting their growth.

The research will provide a detailed qualitative and quantitative product type segment analysis for the years 2021 to 2028.

The report study analyses and includes a variety of prospective prospects and aspects affecting various applications.
 
Ataxia Market Regional Trends and Market Player’s Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the regions in which the market is divided. In 2020, the worldwide Ataxia market was dominated by North America. The Asia Pacific region is expected to have the highest CAGR for the Ataxia market throughout the projected period.


 
The market revenue, market shares, business strategies, recent developments, and growth rates of major players with substantial market shares in the global Ataxia market are all examined. These firms' recent developments, such as new solution/product launches, research projects, acquisitions, geographic expansions, and technological advancements, are taken into account when determining their position in the Ataxia market. All important stakeholders in the Ataxia value chain and technological ecosystem are expected to benefit from the insights offered in the Ataxia market research study.

In order to provide a broader understanding of the top competitors in the Ataxia market, the research includes a company market share analysis. CRISPR Therapeutics, GlaxoSmithKline plc, Capsida Biotherapeutics Inc., Pfizer Inc., Bio-Techne, Acorda Therapeutics, Cellectis SA, Larimar Therapeutics Inc., H. Lundbeck A/S, Sanofi, bluebird bio Inc., Merck & Co. Inc., Editas Medicine, Cellectis SA, Healx, Allergan, and Intellia Therapeutics Inc., others. are among the major participants in the global Ataxia industry.
 
Scope of the report
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2021
Forecast Period Covered 2021-2028
Units for value Revenue in USD million and CAGR from 2021 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered CRISPR Therapeutics, GlaxoSmithKline plc, Capsida Biotherapeutics Inc., Pfizer Inc., Bio-Techne, Acorda Therapeutics, Cellectis SA, Larimar Therapeutics Inc., H. Lundbeck A/S, Sanofi, bluebird bio Inc., Merck & Co. Inc., Editas Medicine, Cellectis SA, Healx, Allergan, and Intellia Therapeutics Inc., others.
 
Major Highlights of the Ataxia Market report study:
  • An in-depth examination of the global Ataxia industry will be published soon.
  • The study examines the global Ataxia market and offers major actionable information to its players.
  • The research has taken into account all key events in the recent past, providing users with up-to-date industry information.
  • The report study is expected to aid the industry's key decision-makers in their decision-making process.
  • Data on market intelligence, changing market dynamics, existing and predicted market trends, and so on are included in the report.
  • The research includes a detailed examination of the macroeconomic and microeconomic aspects that influence the global Ataxia industry.
  • The Market Ecosystem and Adoption in Different Markets
  • The global Ataxia market is being shaped by several major trends.
  • The size of the Ataxia market in terms of revenue has been measured in the past and will be measured in the future in USD million.
  • Consumer preference patterns and recent industrial developments
  • The worldwide Ataxia market's competitive landscape and player positioning analysis
  • Major players' key goods and solutions, as well as their business strategies
  • Recommendations for new market entrants as well as existing market participants.
  • The study of niche and potential segments (product type, application, and regions/countries) predicts that promising growth will be noticed.
  • Operating players in the market encounter a number of significant hurdles.
  • An examination of the major risks involved in market operations
 
The report segment of the global Ataxia market as follows:
Global Ataxia Market: By Product Type

  • Idiopathic
  • Acquired Ataxia
  • Genetic Ataxia

Global Ataxia Market: By Application
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Ataxia Market: By Region
  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China 
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The report study is drafted to provide actionable insights to the following mentioned audience:
  • Institutes of research and consulting firms
  • Companies are attempting to get into the Ataxia market.
  • Universities and students
  • Other companies in the Ataxia market include solution providers, product producers, service providers, and others.
  • Private companies and government agencies that are linked
  • Individuals interested in learning more about the Ataxia market

Manufacturers and Segments

  • CRISPR Therapeutics
  • GlaxoSmithKline plc
  • Capsida Biotherapeutics Inc.
  • Pfizer Inc.
  • Bio-Techne
  • Acorda Therapeutics
  • Cellectis SA
  • Larimar Therapeutics Inc.
  • H. Lundbeck A/S
  • Sanofi
  • bluebird bio Inc.
  • Merck & Co. Inc.
  • Editas Medicine
  • Cellectis SA
  • Healx
  • Allergan
  • and Intellia Therapeutics Inc.
  • others.
  • Idiopathic
  • Acquired Ataxia
  • Genetic Ataxia
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Ataxia Market Snapshot
          2.1.1. Global Ataxia Market By Idiopathic,2019
               2.1.1.1.
               2.1.1.2.Idiopathic
               2.1.1.3.Acquired Ataxia
          2.1.2. Global Ataxia Market By Hospital Pharmacies,2019
               2.1.2.1.
               2.1.2.2.Hospital Pharmacies
               2.1.2.3.Online Pharmacies
          2.1.3. Global Ataxia Market By End-use,2019
          2.1.4. Global Ataxia Market By Geography,2019

3. Global Ataxia Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Ataxia Market Size (US$), By Idiopathic, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Idiopathic, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Idiopathic, 2020
     4.2. Global Ataxia Market Size (US$), By Idiopathic, 2018 – 2028

5. Global Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Hospital Pharmacies, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Hospital Pharmacies, 2020
     5.2. Global Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028

6. Global Ataxia Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Ataxia Market Size (US$), By End-use, 2018 – 2028

7. Global Ataxia Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Ataxia Market Analysis, 2018 – 2028 
          7.2.1. North America Ataxia Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Ataxia Market Size (US$), By Idiopathic, 2018 – 2028
          7.2.3. North America Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028
          7.2.4. North America Ataxia Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Ataxia Market Analysis, 2018 – 2028 
          7.3.1.  Europe Ataxia Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Ataxia Market Size (US$), By Idiopathic, 2018 – 2028
          7.3.3. Europe Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028
          7.3.4. Europe Ataxia Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Ataxia Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Ataxia Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Ataxia Market Size (US$), By Idiopathic, 2018 – 2028
          7.4.3. Asia Pacific Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028
          7.4.4. Asia Pacific Ataxia Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Ataxia Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Ataxia Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Ataxia Market Size (US$), By Idiopathic, 2018 – 2028
          7.5.3. Latin America Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028
          7.5.4. Latin America Ataxia Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Ataxia Market Analysis, 2018 – 2028 
          7.6.1.  MEA Ataxia Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Ataxia Market Size (US$), By Idiopathic, 2018 – 2028
          7.6.3. MEA Ataxia Market Size (US$), By Hospital Pharmacies, 2018 – 2028
          7.6.4. MEA Ataxia Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Ataxia Providers
        8.4.1 CRISPR Therapeutics
                8.4.1.1 Business Description
                8.4.1.2 CRISPR Therapeutics Geographic Operations
                8.4.1.3 CRISPR Therapeutics Financial Information
                8.4.1.4 CRISPR Therapeutics Product Positions/Portfolio
                8.4.1.5 CRISPR Therapeutics Key Developments
        8.4.2 GlaxoSmithKline plc
                8.4.2.1 Business Description
                8.4.2.2 GlaxoSmithKline plc Geographic Operations
                8.4.2.3 GlaxoSmithKline plc Financial Information
                8.4.2.4 GlaxoSmithKline plc Product Positions/Portfolio
                8.4.2.5 GlaxoSmithKline plc Key Developments
        8.4.3 Capsida Biotherapeutics Inc.
                8.4.3.1 Business Description
                8.4.3.2 Capsida Biotherapeutics Inc. Geographic Operations
                8.4.3.3 Capsida Biotherapeutics Inc. Financial Information
                8.4.3.4 Capsida Biotherapeutics Inc. Product Positions/Portfolio
                8.4.3.5 Capsida Biotherapeutics Inc. Key Developments
        8.4.4 Pfizer Inc.
                8.4.4.1 Business Description
                8.4.4.2 Pfizer Inc. Geographic Operations
                8.4.4.3 Pfizer Inc. Financial Information
                8.4.4.4 Pfizer Inc. Product Positions/Portfolio
                8.4.4.5 Pfizer Inc. Key Developments
        8.4.5 Bio-Techne
                8.4.5.1 Business Description
                8.4.5.2 Bio-Techne Geographic Operations
                8.4.5.3 Bio-Techne Financial Information
                8.4.5.4 Bio-Techne Product Positions/Portfolio
                8.4.5.5 Bio-Techne Key Developments
        8.4.6 Acorda Therapeutics
                8.4.6.1 Business Description
                8.4.6.2 Acorda Therapeutics Geographic Operations
                8.4.6.3 Acorda Therapeutics Financial Information
                8.4.6.4 Acorda Therapeutics Product Positions/Portfolio
                8.4.6.5 Acorda Therapeutics Key Developments
        8.4.7 Cellectis SA
                8.4.7.1 Business Description
                8.4.7.2 Cellectis SA Geographic Operations
                8.4.7.3 Cellectis SA Financial Information
                8.4.7.4 Cellectis SA Product Positions/Portfolio
                8.4.7.5 Cellectis SA Key Developments
        8.4.8 Larimar Therapeutics Inc.
                8.4.8.1 Business Description
                8.4.8.2 Larimar Therapeutics Inc. Geographic Operations
                8.4.8.3 Larimar Therapeutics Inc. Financial Information
                8.4.8.4 Larimar Therapeutics Inc. Product Positions/Portfolio
                8.4.8.5 Larimar Therapeutics Inc. Key Developments
        8.4.9 H. Lundbeck A/S
                8.4.9.1 Business Description
                8.4.9.2 H. Lundbeck A/S Geographic Operations
                8.4.9.3 H. Lundbeck A/S Financial Information
                8.4.9.4 H. Lundbeck A/S Product Positions/Portfolio
                8.4.9.5 H. Lundbeck A/S Key Developments
        8.4.10 Sanofi
                8.4.10.1 Business Description
                8.4.10.2 Sanofi Geographic Operations
                8.4.10.3 Sanofi Financial Information
                8.4.10.4 Sanofi Product Positions/Portfolio
                8.4.10.5 Sanofi Key Developments
        8.4.11 bluebird bio Inc.
                8.4.11.1 Business Description
                8.4.11.2 bluebird bio Inc. Geographic Operations
                8.4.11.3 bluebird bio Inc. Financial Information
                8.4.11.4 bluebird bio Inc. Product Positions/Portfolio
                8.4.11.5 bluebird bio Inc. Key Developments
        8.4.12 Merck & Co. Inc.
                8.4.12.1 Business Description
                8.4.12.2 Merck & Co. Inc. Geographic Operations
                8.4.12.3 Merck & Co. Inc. Financial Information
                8.4.12.4 Merck & Co. Inc. Product Positions/Portfolio
                8.4.12.5 Merck & Co. Inc. Key Developments
        8.4.13 Editas Medicine
                8.4.13.1 Business Description
                8.4.13.2 Editas Medicine Geographic Operations
                8.4.13.3 Editas Medicine Financial Information
                8.4.13.4 Editas Medicine Product Positions/Portfolio
                8.4.13.5 Editas Medicine Key Developments
        8.4.14 Cellectis SA
                8.4.14.1 Business Description
                8.4.14.2 Cellectis SA Geographic Operations
                8.4.14.3 Cellectis SA Financial Information
                8.4.14.4 Cellectis SA Product Positions/Portfolio
                8.4.14.5 Cellectis SA Key Developments
        8.4.15 Healx
                8.4.15.1 Business Description
                8.4.15.2 Healx Geographic Operations
                8.4.15.3 Healx Financial Information
                8.4.15.4 Healx Product Positions/Portfolio
                8.4.15.5 Healx Key Developments
        8.4.16 Allergan
                8.4.16.1 Business Description
                8.4.16.2 Allergan Geographic Operations
                8.4.16.3 Allergan Financial Information
                8.4.16.4 Allergan Product Positions/Portfolio
                8.4.16.5 Allergan Key Developments
        8.4.17 and Intellia Therapeutics Inc.
                8.4.17.1 Business Description
                8.4.17.2 and Intellia Therapeutics Inc. Geographic Operations
                8.4.17.3 and Intellia Therapeutics Inc. Financial Information
                8.4.17.4 and Intellia Therapeutics Inc. Product Positions/Portfolio
                8.4.17.5 and Intellia Therapeutics Inc. Key Developments
        8.4.18 others.
                8.4.18.1 Business Description
                8.4.18.2 others. Geographic Operations
                8.4.18.3 others. Financial Information
                8.4.18.4 others. Product Positions/Portfolio
                8.4.18.5 others. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Ataxia Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Ataxia Market Revenue, By Idiopathic, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Ataxia Market Revenue, By Hospital Pharmacies, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Ataxia Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Ataxia Market Revenue, By Idiopathic, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Ataxia Market Revenue, By Hospital Pharmacies, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Ataxia Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Ataxia Market Revenue, By Idiopathic, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Ataxia Market Revenue, By Hospital Pharmacies, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Ataxia Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Ataxia Market Revenue, By Idiopathic, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Ataxia Market Revenue, By Hospital Pharmacies, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Ataxia Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Ataxia Market Revenue, By Idiopathic, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Ataxia Market Revenue, By Hospital Pharmacies, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Ataxia Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Ataxia: Market Segmentation 
FIG. 2 Global Ataxia Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Ataxia Market, By Idiopathic, 2019 (US$ Mn) 
FIG. 5 Global Ataxia Market, By Hospital Pharmacies, 2019 (US$ Mn) 
FIG. 6 Global Ataxia Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Ataxia Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Ataxia Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Ataxia Providers, 2019
FIG. 11 Global Ataxia Market Revenue Contribution, By Idiopathic, 2019 & 2028 (Value %) 
FIG. 12 Global Ataxia Market Revenue Contribution, By Hospital Pharmacies, 2019 & 2028 (Value %) 
FIG. 13 Global Ataxia Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Ataxia Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Ataxia Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Ataxia Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Ataxia Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Ataxia Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Ataxia market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Ataxia Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Ataxia Market Value, By Segment1, 2018 – 2028
TABLE  North America Ataxia Market Value, By Segment2, 2018 – 2028
TABLE  North America Ataxia Market Value, By Country, 2018 – 2028
TABLE  Europe Ataxia Market Value, By Segment1, 2018 – 2028
TABLE  Europe Ataxia Market Value, By Segment2, 2018 – 2028
TABLE  Europe Ataxia Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Ataxia Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Ataxia Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Ataxia Market Value, By Country, 2018 – 2028
TABLE  Latin America Ataxia Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Ataxia Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Ataxia Market Value, By Country, 2018 – 2028
TABLE  MEA Ataxia Market Value, By Segment1, 2018 – 2028
TABLE  MEA Ataxia Market Value, By Segment2, 2018 – 2028
TABLE  MEA Ataxia Market Value, By Country, 2018 – 2028
TABLE  CRISPR Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Capsida Biotherapeutics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bio-Techne: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Acorda Therapeutics: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cellectis SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Larimar Therapeutics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  H. Lundbeck A/S: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  bluebird bio Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck & Co. Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Editas Medicine: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cellectis SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Healx: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Allergan: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  and Intellia Therapeutics Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  others.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Ataxia Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Ataxia Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Ataxia Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Ataxia Market, By Geography, 2019 (US$ Mn)
FIG.  Global Ataxia Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Ataxia Providers, 2016
FIG.  Global Ataxia Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Idiopathic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Acquired Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Genetic Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ataxia Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Hospital Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Online Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Retail Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Ataxia Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Ataxia Market Value, 2018 – 2028, (US$ Mn)